share_log

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Novocure Secures New $400M Non-Dilutive Debt Financing From Pharmakon

Novocure從Pharmakon獲得新的4億美元非稀釋性債務融資
Benzinga ·  05/02 07:18

Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and settle, upon maturity, Novocure's convertible notes

使用所得款項爲Novocure預計在非小細胞肺癌領域上市所產生的營運資金需求提供資金,並在到期時結算Novocure的可轉換票據

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論